Please find attached the Press Release on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended on June 30, 2026

July 23, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400051 Mumbai- 400001 (SYMBOL: THYROCARE) (SCRIP CODE: 539871) Sub: Press Release on Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026 Ref: Disclosure under Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/ Madam, Please find enclosed - the Press Release on the unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. The same is also being made available on the Company’s website https://investor.thyrocare.com/ We request you to please take the same on record. Yours Faithfully, For Thyrocare Technologies Limited, Brijesh Kumar Company Secretary and Compliance Officer Encl. A/a NEWS Release Thyrocare Technologies Limited reports revenue of INR 240.02 Cr in Q1FY27 with a growth of 24% YoY Revenue EBITDA PAT INR 240.02 Cr INR 77.27 Cr INR 51.33 Cr 24% YoY 34% YoY 34% YoY Navi Mumbai, July 23, 2026 Thyrocare Technologies Limited (hereinafter referred to as “Thyrocare” NSE: THYROCARE, BSE: 539871), a leading healthcare diagnostics company, announces their results for the quarter ended June 30, 2027. From Routine to Remarkable: The Next Frontier of Diagnostics • Thyrocare expanded into Specialty Diagnostics, marking the next phase of its growth journey and the next frontier of diagnostics. The Company commenced this journey with Allergy and Genomics and progressively expanded its specialty test portfolio, with a focus on building clinical trust through scientific rigor, uncompromising quality, and industry-leading turnaround times K ey Financial Highlights for Q1FY27 • Consolidated revenue registered a 24% year-on-year growth, driven primarily by a 26% increase in the Pathology segment • In the Pathology business, franchise revenue grew by 27% year-on-year, while partnership revenue recorded 26% year-on-year growth • Thyrocare, India’s largest diagnostic test volume processor, processed 55.2 million tests in Q1FY27, marking a strong 28% year-on-year growth and reinforcing its volume leadership position in the industry • Consolidated EBITDA grew by 34% year-on-year to Rs 77.27 Cr, and Profit After Tax (PAT) grew by 34% year-on-year to Rs 51.33 Cr • Sustained Six Sigma quality standards, reducing complaints per million tests to 3.1 (down 24% YoY) with ATAT at 3.37 hours - India's first diagnostic chain to hit this benchmark Thyrocare Reports Robust Q1FY27 Results – Revenue Up 24%, PAT Up 34% The company delivered a robust performance in Q1FY27 with consolidated revenue of ₹240.02 crore, registering a strong 24% year-on-year growth, led by continued momentum in the Pathology segment which grew 26% YoY. EBITDA rose by 34% YoY to ₹77.27 crore. Profit After Tax surged 34% YoY to ₹51.33 crore, underscoring the company’s focus on profitable growth. India’s largest diagnostic test volume processor further strengthened its volume leadership position during the quarter, processing 55.2 million tests up 28% year-on-year. The Pathology business maintained strong traction with franchise revenue up 27% and partnership revenue up 26% year- on-year. Thyrocare's unwavering commitment to quality delivered Six Sigma excellence by reducing complaints to 3.1 per million (down 24% YoY) with ATAT at 3.37 hours from sample receipt, positioning the company as India's first diagnostic chain to attain this benchmark. Thyrocare expanded into Specialty Diagnostics, marking the next phase of its growth journey and the next frontier of diagnostics. The Company commenced this journey with Allergy and Genomics and progressively expanded its specialty test portfolio, with a focus on building clinical trust through scientific rigor, uncompromising quality, and industry-leading turnaround times Senior management remarks: “Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expand its reach in underserved regions and scale its franchise and partner network, while remaining committed to delivering high-quality, affordable healthcare services across India” – Rahul Guha, MD & CEO, Thyrocare Technologies Ltd Consolidated Financial Performance for Q1FY27 About Thyrocare Thyrocare Technologies Limited (NSE: THYROCARE, BSE: 539871) is India's first and foremost advanced fully automated laboratory chain with strong presence PAN India. Thyrocare focuses on providing quality and affordable diagnostic services to patients, healthtech and wellness providers, insurance companies, pharmaceutical companies, franchisees, laboratories, hospitals and the government. Many leading healthcare product and services brands all over India use the comprehensive test profile menu offered by Thyrocare. Thyrocare has an extensive network of laboratories across PAN India. Thyrocare has a Quarterly active franchise count of ~11,700 and processed 55.2mn diagnostic and screening investigations in Q1FY27. Thyrocare is one of the first Indian diagnostic laboratories to obtain internationally renowned quality accreditations including ISO 9001-2000 rating as early as 2001, which was upgraded to ISO 9001:2015 and National Accreditation Board for Testing and Calibration Laboratories (NABL) and College of American Pathologists (CAP) accreditations in 2005. Safe harbor statement Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward- looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Both the companies assume no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors. For further details please contact: Brijesh Kumar Company Secretary and Compliance Officer brijesh.jha@thyrocare.com +91 84229 45537 Company: Thyrocare Technologies Limited CIN: L85110MH2000PLC123882 Website: www.thyrocare.com